INS webinars deliver the most current infusion-related topics in a 60-minute presenter-led session. Each webinar is delivered live and then archived for on-demand viewing. All webinars are free to INS members.

Webinars

Search by Format
Sort By
Search by Keyword
  • Contains 3 Component(s) Includes a Live Web Event on 10/05/2022 at 1:00 PM (EDT)

    Gout is a type of arthritis that occurs when extra uric acid in the body forms crystals in the joints, causing pain and swelling. Early diagnosis and treatment of gout are important to prevent complications. During this presentation, the presenter will provide an overview of gouty arthritis, discuss the patient’s journey, and elaborate on the principles and guidelines for the management of gout as well as on the associated comorbidities.

    image

    Gout is a type of arthritis that occurs when extra uric acid in the body forms crystals in the joints, causing pain and swelling. Early diagnosis and treatment of gout are important to prevent complications. During this presentation, the presenter will provide an overview of gouty arthritis, discuss the patient’s journey, and elaborate on the principles and guidelines for the management of gout as well as on the associated comorbidities.

    Learning Objectives: At the conclusion of this session, the learner will be able to:
    1. Define the disease state of gout
    2. Discuss the pathophysiology of gout
    3. Review principles of disease management

    *There are no Contact Hours or Recertification Units provided for this webinar

    Vikram Garg, MD

    Vikram Garg, MD, is a board-certified physician in internal medicine, rheumatology, and musculoskeletal ultrasound. He has over six years of direct patient care and teaching experience with assessment and treatment of all rheumatic conditions including rheumatoid arthritis, lupus, and gout.

  • Contains 3 Component(s), Includes Credits Recorded On: 09/14/2022

    Iron deficiency anemia (IDA) is a common diagnosis which occurs when body iron stores fall below the necessary levels to maintain steady state hemoglobin. IDA can be categorized into two main causes, low iron input (inadequate dietary intake or malabsorption) or increased iron output (usually from blood loss and rarely with urinary iron loss such as in nephrotic syndrome).

    image

    Iron deficiency anemia (IDA) is a common diagnosis which occurs when body iron stores fall below the necessary levels to maintain steady state hemoglobin. IDA can be categorized into two main causes, low iron input (inadequate dietary intake or malabsorption) or increased iron output (usually from blood loss and rarely with urinary iron loss such as in nephrotic syndrome). 

    The topic of discussion will include basics of interpreting common labs used for diagnosing anemia including complete blood count (CBC), iron panel (including ferritin), B12/Folate, and lactate dehydrogenase (LDH) to help differentiate iron deficiency anemia from other causes such as anemia of chronic disease, bone marrow suppression from drugs, chronic kidney disease, or chronic hemolysis. First line treatment for iron deficiency anemia is often oral iron supplements, but when patient has a lack of response, or an intolerance to oral iron, IV iron infusions can restore the iron deficit. During this webinar, we will discuss the causes of IDA, the symptoms of IDA, safe IV iron infusion administration, and potential complications of IV iron infusions.

    Learning Objectives: At the conclusion of this session, learners will be able to:

    1. Interpret commons labs used to differentiate iron deficiency anemia from other causes of anemia
    2. Describe the causes of and symptoms of IDA
    3. Review common treatment algorithms for treatment of iron deficiency
    4. Recognize the indications for intravenous iron replacement
    5. Discuss process for safe IV iron infusion administration
    6. Review common potential complications of iron administration and appropriate interventions

    Dr. Christopher Chen

    Dr. Christopher Chen received his undergraduate degree from Washington University in St. Louis with a BA in finance and biology. He then received both his medical degree and an MBA from the State University of New York at Buffalo after which he completed his residency and fellowship at the University of Arizona, Tucson. He is board certified in internal medicine, hematology, and oncology, and has been a preceptor for both the medical school and residency programs in Tucson since 2019.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: September14, 2025

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Contains 3 Component(s), Includes Credits

    ​The United States is in the midst of the opioid epidemic which has claimed more lives in 2021 than in any previous year. The epidemic is being fueled by potent synthetic opioids and at the same time a rising use of methamphetamine with more dangerous sequelae due to the changes in production. Nurses in all settings will care for individuals who may be experiencing pain but also may be using substances that jeopardize their health. In this session an overview of approaches to pain management will be outlined. The presenter will describe the use of trauma-informed care and harm reduction principles as a basis for providing compassionate care to this vulnerable population.

    The United States is in the midst of the opioid epidemic which has claimed more lives in 2021 than in any previous year.  The epidemic is being fueled by potent synthetic opioids and at the same time a rising use of methamphetamine with more dangerous sequelae due to the changes in production.  Nurses in all settings will care for individuals who may be experiencing pain but also may be using substances that jeopardize their health. In this session an overview of approaches to pain management will be outlined.  The presenter will describe the use of trauma-informed care and harm reduction principles as a basis for providing compassionate care to this vulnerable population.

    Learning Objectives:  At the conclusion of this presentation, learners will be able to:

    1.     Describe substance use disorders and relation to pain

    2.     Gain insight into relevance of trauma-informed care in the health care setting

    3.     Discuss elements of harm reduction relevant to work with patients across the continuum

    4.     Describe general approaches utilized to manage pain in the setting of comorbid substance use disorder

    Kathleen Broglio, DNP, ANP-BC, ACHPN, CPE, FPCN, FAANP

    Kathleen Broglio is an associate professor of medicine at Geisel School of Medicine at Dartmouth College and a nurse practitioner in palliative medicine at Dartmouth Hitchcock Medical Center. Her studies have included the prevalence of opioid risk in oncology; cannabis use in palliative medicine; implementation of opioid management guidelines in palliative care; and interprofessional education in palliative and hospice. Kathleen’s clinical care focuses on complex pain management and treatment of substance use disorder in patients with serious illness. She mentors clinicians, lectures and has published on the treatment of pain in the setting of risks for substance use disorder. Her experience includes acute and chronic pain management; and acute, ambulatory, and home-based palliative care. She completed her Doctorate in Nursing Practice at New York University; a Palliative Care Fellowship at Beth Israel Medical Center, New York; a master’s in nursing at University of Washington, Seattle; a bachelor’s in nursing at University of Hawaii; and a bachelor’s in economics at University of Maryland.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: August 16, 2025

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Contains 3 Component(s), Includes Credits Recorded On: 07/06/2022

    ​With the growing recognition of the infection risks of peripheral intravenous catheters (PIVC), many hospitals are implementing PIVC insertion and maintenance bundles. This presentation will review the evidence for PIVC bundles, discuss the essential components for such a bundle, explore implementation challenges, and emphasize compliance strategies. Infusion nurses who are considering implementing a PIVC insertion or maintenance bundle will benefit from this presentation.

    With the growing recognition of the infection risks of peripheral intravenous catheters (PIVC), many hospitals are implementing PIVC insertion and maintenance bundles. This presentation will review the evidence for PIVC bundles, discuss the essential components for such a bundle, explore implementation challenges, and emphasize compliance strategies. Infusion nurses who are considering implementing a PIVC insertion or maintenance bundle will benefit from this presentation.

    Learning Objectives: At the conclusion of this session, learners will be able to: 

    1.     Describe the common reasons for PIVC failure and the prevalence of PIVC bloodstream infection.

    2.     Review the history and rationale of the evidence-based bundle for bloodstream infection reduction.

    3.     Discuss the rationale for implementing a PIVC insertion and maintenance bundle.

    4.     Identify bundle components which have demonstrated reductions in PIVC–related bloodstream infection and other adverse events.

    5.     Discuss the challenges of bundle implementation and possible strategies to achieve compliance.

    Gillian Ray-Barruel, PhD, RN

    Senior Research Fellow

    University of Queensland School of Nursing, Midwifery, and Social Work

    Gillian Ray-Barruel, PhD, RN, is a senior research fellow with the University of Queensland School of Nursing, Midwifery, and Social Work and the Herston Infectious Diseases Institute (HeIDI), and an adjunct senior research fellow with Griffith University in Brisbane, Australia. She is also the education director for the Alliance for Vascular Access Teaching and Research (AVATAR). An experienced critical care nurse for 20 years, Dr. Ray-Barruel moved into vascular access research over 10 years ago and has published over 60 journal articles. Her research focuses on improving assessment and decision-making by clinicians to prevent device-related patient complications and to improve health care outcomes.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: July 6, 2025

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.

  • Contains 3 Component(s), Includes Credits Recorded On: 06/15/2022

    ​Management of hypersensitivity infusion reactions (IRs) with H1-antihistamine premedication and/or treatment is recommended for several biologics and chemotherapies used in infusion centers. The sole second-generation intravenous H1-antihistamine recommended is cetirizine. In this session, the presenter will review key clinical data available with IV cetirizine as well as clinical profiles of first- and second-generation H1 antihistamines used to manage infusion reactions.

    image

    Management of hypersensitivity infusion reactions (IRs) with H1-antihistamine premedication and/or treatment is recommended for several biologics and chemotherapies used in infusion centers. The sole second-generation intravenous H1-antihistamine recommended is cetirizine. In this session, the presenter will review key clinical data available with IV cetirizine as well as clinical profiles of first- and second-generation H1 antihistamines used to manage infusion reactions.

    Learning Objectives: At the conclusion of this webinar, learners will be able to: 

    • Explain various infusion reactions and antihistamine use

    • Determine infusion reactions requiring a H1-antihistamine to treat a reaction or to prevent future reactions

    • Describe the use of IV H1-antihistamines

    • Determine which treatment options are the most appropriate for certain patients

    Ryan Haumschild, PharmD, MS, MBA

    Ryan Haumschild, PharmD, MS, MBA, is an experienced director of pharmacy, overseeing profit and loss responsibility, pharmacy operations, clinical services, formulary management, payer and health plan contracting, and medication use at the Winship Cancer Institute at Emory University, one of the nation’s largest academic integrated delivery networks and Georgia’s only National Cancer Institute (NCI)–designated comprehensive cancer center. Dr. Haumschild provides strategic direction on oncology and nononcology disease states, on infusion and specialty pharmacy services, and on the expansion of clinical services through treatment pathway development. He currently serves as an editorial board member at the American Journal of Managed Care® (AJMC®) and as a board member for the Institute of Safe Medication Practices (ISMP) and for the Center for Biosimilars, and was recently recognized as 40 under 40 by three separate organizations: University of Florida, Atlanta Business Chronicle, and Association for Value-Based Cancer Care.

    CRNI® RUs: This session has been approved for 2 CRNI® recertification units and meets the non INS Meeting criteria.

    Contact Hours: This session has been approved for 1 contact hour

    Expiration date for receipt of contact hours: June 15, 2025

    To receive contact hours for this educational activity, you are required to attend the entire educational activity and complete the evaluation.

    The Infusion Nurses Society is approved as a provider of continuing nursing education by the California Board of Registered Nursing, provider #CEP14209. The certificate must be retained by the attendee for a period of 4 years.